Inotiv, inc. announces the launch of new genetically engineered rodent models for sars-cov-2 (covid-19) research

West lafayette, ind., dec. 13, 2021 (globe newswire) -- inotiv, inc. (nasdaq: notv) (the “company”, “we”, “our” or “inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that its research models and services (“rms”) business, consisting of recently-acquired envigo, has launched novel transgenic rodent models designed specifically for sars-cov-2 (covid-19) and coronavirus research.
NOTV Ratings Summary
NOTV Quant Ranking